$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Whether aprocitentan is included in medical insurance and its reimbursement ratio and self-payment
2026-02-01 22:25:32
Check Details
Analysis of the target and physiological mechanism of action of tilpotide/tilsiparatide (Mufenda)
2026-02-01 22:25:32
Check Details
Analysis of whether the disease will relapse rapidly after discontinuation of Pitobrutinib/Pitobrutinib (Zepali)
2026-02-01 22:25:32
Check Details
Is the dosage form of Talazoparib (Tazena) capsules or other forms?
2026-02-01 22:25:32
Check Details
Crizotinib price and reference after medical insurance reimbursement in 2026
2026-02-01 22:25:32
Check Details
Mechanism and pharmacological analysis of aprocitentan in the treatment of pulmonary arterial hypertension
2026-02-01 22:25:32
Check Details
Clinical application effect of tilpotide/tilsiparatide (Mufenda) in the treatment of diabetes
2026-02-01 22:25:32
Check Details
Comprehensive explanation of the mechanism of action and clinical efficacy of Pitobrutinib/Pitobrutinib (Zepali)
2026-02-01 22:25:32
Check Details
Safety analysis of combined use of talazoparib (Tazena) and enzalutamide
2026-02-01 22:25:32
Check Details
Analysis of whether crizotinib (Xalkori) is the last line of treatment for patients
2026-02-01 22:25:32
Check Details
Detailed analysis and explanation of pharmacological effects, indications and clinical application value of Omarigliptin tablets
2026-02-01 22:25:32
Check Details
Where can I buy lecanemab-LEQEMBI in the country?
2026-02-01 22:25:32
Check Details
1
2
...
2360
2361
2362
2363
2364
2365
2366
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
2
From Causes to Treatments—Exploring Medical Breakthroughs
3
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
4
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
5
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
6
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
7
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
8
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
9
User Agreement
10
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
11
What is the most important information I should know about WELIREG?
12
How to take and store WELIREG